Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)
Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
Sponsor: Columbia University
Terminated
The primary reason for study closure is slow enrollment.
Other terminated trials from Columbia University
Other Graft Vs Host Disease trials with similar outcome
This PHASE1 trial investigates Graft Vs Host Disease and Steroid Refractory GVHD and is currently terminated or withdrawn. Columbia University leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE1
-
Feb 2021 — Jun 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .